Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in lung fibrosis and stroke. With origins as a spinout from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 20 countries. Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Brainomix e-Lung is an FDA-cleared, AI-powered imaging software platform that automatically quantifies and segments CT lung scans, and has been clinically validated to quantify lung features consistent with ILD.